Table 1. Baseline drug resistance and treatment characteristics of patients, by country (n = 1,137).
| Characteristic | Country | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Estonia | Latvia | Peru | Philippines | Russian Federation | South Africa | South Korea | Taiwan | Thailand | |
| Number of patients included in analysis | 22 | 80 | 162 | 374 | 86 | 252 | 75 | 38 | 48 |
| Site approved by Green Light Committee | Yes | Yes | Yes | Yes | Yes | No | No | No | No |
| Number of drugs to which TB resistant at baseline * | 5 (3–8) | 5 (2–10) | 4 (2–9) | 5 (2–8) | 5 (2–9) | 4 (2–10) | 4 (2–9) | 3 (2–7) | 4 (2–8) |
| Resistance pattern at baseline † | |||||||||
| MDR only | 13 (59%) | 41 (51%) | 135 (83%) | 348 (93%) | 56 (65%) | 195 (77%) | 53 (71%) | 30 (79%) | 43 (90%) |
| MDR with resistance to any second-line injectable | 6 (27%) | 34 (43%) | 22 (14%) | 5 (1%) | 22 (26%) | 51 (20%) | 7 (9%) | 1 (3%) | 2 (4%) |
| MDR with resistance to any fluoroquinolone | 3 (14%) | 5 (6%) | 5 (3%) | 21 (6%) | 8 (9%) | 6 (2%) | 15 (20%) | 7 (18%) | 3 (6%) |
| Previous treatment history † | |||||||||
| None | 16 (73%) | 45 (56%) | 24 (15%) | 0 (0%) | 31 (36%) | 9 (4%) | 9 (12%) | 22 (58%) | 2 (4%) |
| First-line drugs only | 2 (9%) | 20 (25%) | 111 (69%) | 330 (88%) | 33 (38%) | 235 (93%) | 28 (37%) | 15 (39%) | 42 (88%) |
| Second-line drugs | 4 (18%) | 14 (18%) | 18 (11%) | 44 (12%) | 18 (21%) | 8 (3%) | 33 (44%) | 1 (3%) | 4 (8%) |
| Unknown | 0 (0%) | 1 (1%) | 9 (6%) | 0 (0%) | 4 (5%) | 0 (0%) | 5 (7%) | 0 (0%) | 0 (0%) |
| Average number of potentially effective drugs received per day † | |||||||||
| 0 to <4 | 1 (5%) | 13 (16%) | 4 (2%) | 76 (20%) | 29 (34%) | 102 (40%) | 17 (23%) | 6 (16%) | 16 (33%) |
| 4 to <5 | 4 (18%) | 27 (34%) | 12 (7%) | 144 (39%) | 35 (41%) | 86 (34%) | 22 (29%) | 12 (32%) | 18 (38%) |
| 5 to <6 | 10 (45%) | 29 (36%) | 47 (29%) | 130 (35%) | 22 (26%) | 55 (22%) | 21 (28%) | 15 (39%) | 13 (27%) |
| 6 or more | 7 (32%) | 11 (14%) | 99 (61%) | 24 (6%) | 0 (0%) | 9 (4%) | 15 (20%) | 5 (13%) | 1 (2%) |
| Patients with initial sputum culture conversion within 6 mo, by average number of potentially effective drugs received ‡ | |||||||||
| 0 to <4 | 0 (0%) | 7 (54%) | 2 (50%) | 70 (92%) | 22 (76%) | 21 (21%) | 6 (35%) | 5 (83%) | 11 (69%) |
| 4 to <5 | 1 (25%) | 24 (89%) | 4 (33%) | 138 (96%) | 26 (74%) | 44 (51%) | 7 (32%) | 10 (83%) | 12 (67%) |
| 5 to <6 | 6 (60%) | 27 (93%) | 28 (59%) | 128 (98%) | 19 (86%) | 44 (80%) | 12 (57%) | 15 (100%) | 13 (100%) |
| 6 or more | 7 (100%) | 7 (64%) | 81 (82%) | 23 (96%) | N/A | 9 (100%) | 12 (80%) | 5 (100%) | 1 (100%) |
| Patients with initial sputum culture conversion within 12 mo, by average number of potentially effective drugs received ‡ | |||||||||
| 0 to <4 | 0 (0%) | 7 (54%) | 2 (50%) | 71 (93%) | 23 (79%) | 28 (27%) | 7 (41%) | 5 (83%) | 13 (81%) |
| 4 to <5 | 1 (25%) | 24 (89%) | 7 (58%) | 139 (97%) | 29 (83%) | 50 (58%) | 8 (36%) | 11 (92%) | 13 (72%) |
| 5 to <6 | 6 (60%) | 27 (93%) | 32 (68%) | 128 (98%) | 19 (86%) | 48 (87%) | 12 (57%) | 15 (100%) | 13 (100%) |
| 6 or more | 7 (100%) | 7 (64%) | 86 (87%) | 23 (96%) | N/A | 9 (100%) | 12 (80%) | 5 (100%) | 1 (100%) |
Initial sputum culture conversion was defined as at least two consecutive negative cultures of sputum samples collected at least 30 d apart.
*Median (range) presented.
†Number (column percent) presented.
‡Number (percent of those who received that number of drugs) presented.
MDR, multidrug resistant; N/A, not applicable.